logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Bridgene Biosciences Announces $12 Million Series A Financing To Advance The Company'S Proprietary Chemoproteomic Platform And Pipeline Of Oncology Programs

May 05, 2021•over 4 years ago

Amount Raised

$12 Million

Round Type

series a

Sunnyvale

Description

BridGene Biosciences, Inc., a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules for high value, yet traditionally undruggable targets, announced today it has raised $12 million in a Series A private financing round led by Wedo Venture Partners with additional participation by Kaitai Capital and Takeda Ventures, alongside existing investor Pangu Venture.

Company Information

Company

Brid Gene Biosciences

Location

Sunnyvale, California, United States

About

BridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat diseases. By utilizing its proprietary chemoproteomic platform IMTACTM, BridGene is able to screen small molecules against all proteins in live cells to discover drug candidates for high value, yet hard-to-drug targets. The ultimate goal is to enable breakthrough small-molecule drug discovery and to expand the mechanisms to treat diseases, with targets previously inaccessible to small molecules. The company is advancing a diversified pipeline of first-in-class drugs for targets in multiple disease areas. For more information, visit http://bridgenebio.com ContactTiberend Strategic Advisors, Inc.Miriam Weber Miller (investors)212-375-2694[email protected] Johanna Bennett (media)212-375-2686[email protected] SOURCE BridGene Biosciences

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech